scholarly journals The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Shengnan Zhang ◽  
Mengjuan Li ◽  
Fangfang Yuan ◽  
Lin Chen ◽  
Ruihua Mi ◽  
...  
Keyword(s):  
T Cell ◽  
Treatment Response ◽  
Peripheral Blood Lymphocyte ◽  
Peripheral Blood ◽  
Blood Lymphocyte ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Dynamic Monitoring ◽  
Lymphocyte To Monocyte Ratio ◽  
Nk T Cell

Abstract Background To investigate the value of dynamic monitoring peripheral blood lymphocyte-to-monocyte (LMR) ratio in evaluating the treatment response and prognosis of patients with extranodal NK/T cell lymphoma (ENKTL). Methods A total of 148 patients with ENKTL were retrospectively analyzed in the Affiliated Tumor Hospital of Zhengzhou University between March 2012 and March 2018. The optimal cut-off value of LMR was determined using the receiver operating characteristic curve (ROC) method, then patients were divided into low LMR group and high LMR group. The LMR level was dynamically measured at various time points, and the relationships between LMR and therapeutic response, and survival were analyzed. Results The complete remission rate (CR) was 85.7% in patients with high LMR at diagnosis, which was remarkably higher than that of patients with low LMR at diagnosis (64.9%) (P = 0.009). The 5-year overall survival (OS) and progression-free survival (PFS) were 49.28% and 44.89% in the low LMR group, respectively; 5-year OS and PFS in the high LMR group were 84.50% and 67.12%, respectively, significantly longer (P values were < 0.001 and 0.034, respectively). The OS and PFS of patients with elevated LMR after treatment were longer than those with decreased LMR after treatment (all P values < 0.05). The LMRs at relapse were significantly lower in both high and low LMR groups than those of the last follow-up (P values were 0.001 and 0.016, respectively). Univariate and multivariate analysis demonstrated that low LMR was an independent risk factor for poor prognosis in ENKTL patients (P values were < 0.001 and 0.009, respectively). Conclusions Lymphocyte to monocyte ratio can be used as an indicator of treatment response, prognosis and recurrence in patients with ENKTL. Low LMR before and after treatment is a poor prognostic factor.

scholarly journals Decreased Peripheral Blood Lymphocyte-Monocyte Ratio and Platelet-Monocyte Ratio and the Peripheral Blood Score Model Predict Poor Survival in Peripheral T-cell Lymphoma Patients

2020 ◽  
Author(s):  
Yan Zhang ◽  
Yuanfei Shi ◽  
Huafei Shen ◽  
Lihong Shou ◽  
Qiu Fang ◽  
...  
Keyword(s):  
T Cell ◽  
High Risk ◽  
Peripheral Blood Lymphocyte ◽  
Peripheral Blood ◽  
Blood Lymphocyte ◽  
Cell Lymphoma ◽  
Risk Group ◽  
Low Risk ◽  
T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma

Abstract Background. Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Its incidence rate in China is 1 to 2 times higher than in western countries. Therefore, optimal strategies for identifying high-risk patients are urgently needed. Methods. We retrospectively studied 347 newly diagnosed PTCL patients from January 2011 to October 2019 and analyzed the relationship between peripheral blood lymphocyte-monocyte ratio (LMR) and platelet-monocyte ratio (PMR) and prognosis. The model of Peripheral Blood Score was established to screen out high-risk patients.Results. The receiver operating characteristic (ROC) curve was used to determine the optimal cut-off value based on survival rate. It was found that patients with PTCL with LMR ≤ 1.68 and PMR ≤ 300 had inferior overall survival (OS) and the difference was significant in both low-risk (P＜0.001) and medium high-risk (P＜0.001) groups of IPI score. In multivariate analysis, LMR ≤ 1.68 (HR=1.751, 95% CI 1.158-2.647, p=0.006), PMR ≤ 300 (HR=1.762, 95% CI 1.201-2.586, p=0.002), stage III-IV (HR=3.276, 95% CI 1.512-7.099, p=0.003), Eastern Cooperative Oncology Group (ECOG) score 3-5 (HR=2.351, 95% CI 1.647-3.356, p＜0.001) and extra-nodal invasion more than one site (HR=1.659, 95% CI 1.125-2.445, p=0.039) were independently associated with short survival. LMR and PMR were integrated into "Peripheral Blood Score (PBS)" model. PTCL patients were divided into three risk groups: low-risk group, medium risk group and high-risk group. The 1-year OS was 86%, 55.3% and 22.6%, and the 3-year OS was 43.4%, 20% and 13.1%, respectively.Conclusion. Overall, LMR and PMR can be used as early prognostic indicators in PTCL patients. Moreover, we can easily detect the complete blood cell count (CBC), and use PBS model to preliminarily screen and stratify patients. It is simple, convenient and accurate to screen out patients with short lives, and formulate personalized treatment strategies.

scholarly journals Flow cytometry characterization of leukemic phase of nasal NK/T-cell lymphoma in tumor biopsies and peripheral blood

Haematologica ◽  
2007 ◽  
Vol 92 (2) ◽  
pp. e24-e25 ◽  
Author(s):  
R.P. Falcao ◽  
E.G. Rizzatti ◽  
F.P. Saggioro ◽  
A.B. Garcia ◽  
A.F. Marinato ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
T Cell ◽  
Peripheral Blood ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Nk T Cell ◽  
Leukemic Phase ◽  
Tumor Biopsies

scholarly journals The Predictive Value of the Peripheral Blood Lymphocyte-to-Monocyte Ratio in Patients with Anaplastic Large Cell Lymphoma

2021 ◽  
Author(s):  
Shengnan Zhang ◽  
Yuqing Chen ◽  
Qian Wang ◽  
Fangfang Yuan ◽  
Hao Ai ◽  
...  
Keyword(s):  
Peripheral Blood Lymphocyte ◽  
Anaplastic Large Cell Lymphoma ◽  
Peripheral Blood ◽  
Blood Lymphocyte ◽  
Cell Lymphoma ◽  
Characteristic Curve ◽  
Large Cell ◽  
High Baseline ◽  
Lymphocyte To Monocyte Ratio ◽  
Large Cell Lymphoma

Abstract BackgroundTo assess the value of the peripheral blood lymphocyte-to-monocyte ratio (LMR) in predicting the early treatment response and prognosis in patients with anaplastic large cell lymphoma (ALCL).MethodsThe optimal cut-off value for the LMR was determined using the receiver operating characteristic curve (ROC) method. The LMR was monitored dynamically, and the relationship between the LMR and therapeutic response, and survival was analyzed.Results The cumulative complete remission (CCR) rate was 57.1% in patients with low baseline LMR, remarkably lower than that for patients with high baseline LMR (80.0%) (P = 0.019). The 5-year overall survival (OS) and progression-free survival (PFS) were 51.3% and 32.6%, respectively, in the low baseline LMR group, which were significantly poorer at 90.4% and 70.5% in the high baseline LMR group, respectively (P values were 0.006 and 0.013, respectively). Furthermore, the median OS and PFS of patients with a decreased LMR after treatment were shorter than those with an elevated LMR after treatment (all P values < 0.05). Univariate and multivariate analysis demonstrated that low baseline LMR is an independent indicator for poor prognosis in ALCL patients (P values were 0.006 and 0.020, respectively). Interestingly, the combination of low baseline LMR and ALK positive could strongly predict the good prognosis in patients with ALCL. ConclusionsThe low baseline LMR and a decreased LMR after treatment are prognostic indicator for poor PFS and OS. The combination of LMR and ALK expression can widely risk-stratify patients for treatment and survival in patients with ALCL.

scholarly journals Diagnostic Value of protocadherin 15 on NK/T Cell Lymphoma

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5396-5396
Author(s):  
Jiali Zhou ◽  
Caigang Xu
Keyword(s):  
T Cell ◽  
Cell Lines ◽  
Peripheral Blood ◽  
Cell Lymphoma ◽  
Normal Population ◽  
T Cell Lymphoma ◽  
Lymphoma Cell ◽  
Control Group ◽  
Nk T Cell ◽  
Experimental Group

Abstract Objective: NK/T cell lymphoma is a unique subtype of non-Hodgkin’s lymphoma, accounting for 5% to 15% of lymphomas, and shows a prediction for the crowd of Asia, central and South America. Nasal, nasopharynx and oropharynx regions are commonly involved. Lesions may also occur in the upper respiratory tract, gastrointestinal tract, testis and other parts. Diagnosis of NK/T cell lymphoma is dependent on the pathological study of lesion biopsy specimens. Nevertheless, poor quantity or quality of specimens, such as tissue extensive necrosis often become an obstacle to the early diagnosis. Therefore, investigating an easy sampling, accurate and stable experimental marker has profound clinical significance for the diagnosis of NK / T-cell lymphoma. Protocadherin15 (PCDH15) is a member of the cadherin family, which encoding gene located on chromosome 10q21-22. Rouget-Quermalet found a secreted isoform PCDH15 in the cracking sediment of human YT-type NK/T-cell lymphoma cell lines 8 years ago. PCDH15 was found not expressed in fresh or activated normal peripheral blood cells, CD4/CD8 positive lymphocytes, NK cells, normal spleen, lymph nodes, tonsils reactivity and CD34 + cord blood cells, only specifically expressed in three kinds of NK cell lymphoma cell lines. PCDH15 was not expressed in the biopsies of diffuse large B-cell lymphoma, mantle cell lymphoma and other types of lymphoma, but specifically expressed in NK/T lymphoma biopsy tissues. Since PCDH15-SI was found in the human NK/T-cell lymphoma cell lines, its relationship with NK / T-cell lymphoma as well as other types of lymphoma was rarely reported, and studies of clinical specimens are still blank. The purpose of this study is to investigate what whether the PCDH15 is specifically expressed in NK/T-cell lymphoma biopsies, and whether the PCDH15-SI, as a secreted isoform, is specifically present in peripheral serum of newly diagnosed NK/T-cell lymphoma or not. Materials and methods: 1. Screening biopsy paraffin blocks of NK/T-cell lymphoma(2010.1～2013.10) and non-NK/T-cell lymphoma(2012.10～2013.11) in West China Hospital of Sichuan University, which have 45cases and 33 cases stained by immunohistochemistry respectively and blank controls were set. 2. Collecting peripheral blood of NK/T-cell lymphoma, non-NK/T-cell lymphoma and normal population in the same Hospita. PCDH15 content of serum samples were detected by enzyme-linked immunosorbent content analysis (ELISA) method. Results: 1. Results of immunohistochemistry showed that PCDH15 were expressed both in the experimental group NK/T-cell lymphoma and the control group with non-NK/T cell lymphoma. High expression rate in the NK/T-cell lymphoma group was higher than in non-NK/T cell lymphoma. The differences of PCDH15 expression levels between the two groups, or among the different anatomical structures were not statistically significant (P > 0.05). 2. PCDH15-SI can be detected in peripheral blood in the normal population, the experimental group of NK/T-cell lymphoma as well as in the control group of non-NK/T-cell lymphoma, which the level of PCDH15-SI in those patients with newly diagnosed disease was higher than that of the normal population and the serum level in the non-NK/T-cell lymphoma patients was higher than that in the NK/T-cell lymphoma patients(P < 0.05). Conclusions: 1. PCDH15 was expressed in biopsies of different types of lymphoma, and the degree of expression in NK/T-cell lymphoma was significantly higher. 2. PCDH15 can’t be used to diagnose NK/T cell lymphoma as a marker. Disclosures No relevant conflicts of interest to declare.

Extranodal NK/T-Cell Lymphoma: A Comparative Clinicopathological Study According to Survival Outcome.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4413-4413
Author(s):  
Yong Won Choi ◽  
Jung Il Park ◽  
Jae Ho Jung ◽  
Sung Heun Jeong ◽  
Hyun Woo Lee ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
T Cell ◽  
Treatment Response ◽  
Cell Lymphoma ◽  
Survival Outcome ◽  
T Cell Lymphoma ◽  
First Year ◽  
Significant Prognostic Factor ◽  
Nk T Cell

Abstract BACKGROUND Extranodal NK/T-cell lymphoma is notable for its unique behavior; Many patients die before 1 year from the diagnosis. However, the patients who survive the first year from the diagnosis live for longer period. Known prognostic factors were insufficient to explain this unique pattern. The objective of this study was to investigate clinicopathological features according to survival outcome(OS<1 yr vs OS ≥1 yrs). METHODS We reviewed 28 patients who diagnosed as extranodal NK/T cell lymphoma from March, 1995 to July, 2006. Patients were treated with chemotherapy alone or chemoradiotherapy. Real-time PCR was done from the tissue of the biopsy specimen to quantify the Epstein-Barr virus load. RESULTS Of the 28 patients, 14 patients(50%) achieved a complete remission(CR). Median survival was 46 months(range, 1–114 months). The B symptoms, IPI score, stage, ECOG status, first treatment response was significant prognostic factor (P<0.05). However ECOG status the only significant prognostic factor by using mutivariate analysis (P=0.001). Seventeen patients (61%) expired; 12 of those patients died during the first year of diagnosis. Thus we divided them into 2 groups; who lived more than 1 year and who lived less than 1 year. The ECOG status, first treatment response rate was different between the two groups significantly(p<0.05). All patients showed positive EBV by PCR. However, there was no significant difference in EBV load between these two groups. (p=0.113) CONCLUSION The ECOG status, and response to the first treatment related to the survival of first year from the diagnosis. For the patients with poor performance status, and failure to achieve CR after the first treatment, more aggressive treatment should be considered to improve survival. In our study, EBV load measured on the paraffin tissue failed to correlate with survival. Univariate Analysis of Overall survival Prognostic Factors Median OS(months) P value Age >60yrs 33 <60yrs 10 0.783 Type Nasal 33 Nasal type 5 0.225 B symptom Yes 5 No 42 0.021 IPI Low/Low-intermediate 42 High-intermediate/High 2 0.002 Stage I/II 42 III/IV 2 0.001 ECOG 0,1 45 2,3,4 2 0.001 LDH Normal 33 High 17 0.720 EBV load(copies/ug DNA)(n=22) 46 0.228 Treatment C/T alone 5 C/T and R/T 42 0.196 treatment response CR 45 No-CR 14 0.0127 Multivariate Analysis of Overall survival Prognostic Factors Hazad Ratio 95% CI P B symptom No 1.00 Yes 0.97 0.11–8.58 0.980 IPI score Low/Low-inermediate 1.00 High-intermediate/High 1.35 0.25–7.26 0.730 Stage I,II 1.00 III,IV 0.60 0.06–6.12 0.668 ECOG 0,1 1.00 2,3,4 6.94 2.23–21.55 0.001 Treatment response CR 1.00 No-CR 1.98 0.56–6.96 0.287 Fig. 2 Overall survival according to survival outcome (OS<1 year vs OS ≥ 1 years). The patients who survive more than 1 year showed relativily good prognosis. Fig. 2. Overall survival according to survival outcome (OS<1 year vs OS ≥ 1 years). The patients who survive more than 1 year showed relativily good prognosis.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1760-1760
Author(s):  
Bing Bai ◽  
Hui-qiang Huang ◽  
Qi-chun Cai ◽  
Xiao-Xiao Wang ◽  
Qingqing Cai ◽  
...  
Keyword(s):  
T Cell ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
Serum Levels ◽  
T Cell Lymphoma ◽  
Dynamic Monitoring ◽  
C Reactive Protein ◽  
Bulky Disease ◽  
Reactive Protein ◽  
Nk T Cell

Abstract The prognostic value of dynamic monitoring C-reactive protein (CRP) serum levels in NK/T-cell lymphoma Background and Objective C-reactive protein (CRP) is a kind of acute phase protein against inflammatory reaction. CRP has been proved to be associated with prognosis in various malignancies. Yet, the prognostic value of CRP in natural killer/T-cell lymphoma (NK/TCL) remains to be discussed. In this study, we aimed to observe the dynamic change of CRP serum levels during anti-lymphoma treatment, and to evaluate the prognostic value of CRP as a simple and economical biomarker during the early stage of treatment in patients with NK/T-cell lymphoma. Patients and Methods Between January 2003 and December 2011, 161 patients with newly diagnosed NK/TCL at the Sun Yat-sen University Cancer Center (SYSUCC) were reviewed retrospectively. Clinical and laboratory information was collected and analyzed. The following CRP serum levels were evaluated: pretreatment CRP (CRP0), early-treatment CRP (CRP1, after one cycle of chemotherapy, or two or three weeks since beginning of radiation), and post-treatment CRP (CRP2, after first-line treatment, or failure of first-line treatment). Results Overall, 161 patients were reviewed and analyzed. The median age was 44 years (range, 11¨C74). The majority had localized disease (stage I/ II; 75.5%). The CRP serum levels (mean ± standard deviation) were as follows: CRP0, 17.2±23.1 mg/L; CRP1, 14.0±30.0 mg/L; CRP2, 14.1±27.0 mg/L. The pretreatment CRP serum levels correlated with others unfavorable factors, including serum lactate dehydrogenase (LDH) (P = 0.005), presence of bulky disease (P = 0.002), presence of B symptoms (P = 0.017), the International Prognostic Index (IPI) score (P = 0.001) and the Korean Prognostic Index (KPI) score (P = 0.001). By the time of the final follow up assessment (May 2013), the median follow-up time was 23.0 months (range, 1.0-106.0 months). The median overall survival (OS) and progression-free survival (PFS) were 45.0 months (range, 1.0-106.0 months) and 32.0 months (range, 1.0-74.0 months), respectively. The independent unfavorable prognostic factors for OS (P < 0.05) in multivariate analysis included: elevated CRP1 (P < 0.001), presence of bulky disease (P = 0.007), and elevated β2-microglobulin (β2-mg) serum levels (P = 0.004). The receiver operating characteristic analysis revealed a similar cut-off value of CRP (8.16 mg/L) to the default value of the biochemical analyzer (8.2 mg/L). In addition, the result suggested a satisfying capacity of CRP1 in predicting response to initial treatment (sensitivity 94%, specificity 74%) and 5-year OS (sensitivity 75%, specificity 90%), among different serum biomarkers, including EBV-DNA, LDH, β2-mg, CRP0, CRP1, and CRP2. In all groups of patients classified according to dynamic CRP values, the patients with CRP0 (+) /CRP1(-) presented the most favorable prognosis (5-year estimated OS: 72.5%). Conclusions Our study suggests that elevated early-treatment CRP is an independent unfavorable prognostic factor for patients with NK/TCL. Compared with the baseline CRP, the dynamic change of CRP levels may provide more important information for prognosis during treatment. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document